Novo Nordisk Announces US Staff Reductions
Novo Nordisk is planning staff reductions of approximately 250 employees in the US as part of a reorganization resulting from an assessment of resource needs against its business priorities. Last month (September 2018), the company announced staff reductions of 400 employees in research and development (R&D) roles in China and Denmark.
The company has not specified which segments the reductions will come from but says those affected will be given an opportunity to apply for open positions within Novo Nordisk.
As part of its restructuring in R&D announced last month, the company said it plans to restructure its R&D organization to accelerate expansion and diversification of its pipeline across chronic diseases. The company said it will set up four Transformational Research Units in 2018 to pursue new treatment modalities and platform technologies. The biotech-like units, based in Denmark, the US and the UK, will operate as satellites of Novo Nordisk’s central R&D function and will drive work in priority fields such as translational cardio-metabolic research and stem-cell research. Additionally, to help molecule selection and development, Novo Nordisk will increase its investment in automation and digital capabilities, including machine learning and artificial intelligence. The integration of laboratory infrastructure and information-technology systems will also be prioritized to increase efficiency.
Source: Novo Nordisk